Crispr Therapeutics price target lowered to $48 from $53 at RBC Capital

RBC Capital analyst Luca Issi lowered the firm’s price target on Crispr Therapeutics (CRSP) to $48 from $53 and keeps a Sector Perform rating on the shares after its Q4 results. Casgevy’s launch is under way with over 50 authorized treatment centers vs. 45 last quarter and cells collected from over 10 patients in Q4, the analyst tells investors in a research note. RBC adds however that while it appreciates all the progress, it remains on the sidelines with a cautious view on Casgevy’s launch while awaiting further progress on the rest of the in vivo pipeline.